Document Detail


Evidence for a dual pathway in platelet activating factor-induced aggregation of rat polymorphonuclear leucocytes.
MedLine Citation:
PMID:  3035617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to determine the role, if any, of Leukotriene B4 (LTB4) in Platelet Activating Factor (PAF)-induced aggregation of rat polymorphonuclear leucocytes (PMNs). Exposure of rat PMNs to 10(-7) M PAF resulted in the release of 4.5 +/- 0.7 ng/10(7) cells of LTB4 measured by radioimmunoassay. However, the maximum aggregation of PMNs achieved by exposure to LTB4 (10(-7)M) was only 50% of that produced by maximally aggregating concentrations of PAF (10(-7)M). 5-Lipoxygenase inhibitors, BW755c and Nafazatrom at concentrations that completely abolished LTB4 synthesis inhibited the aggregation induced by PAF only by 40% and 50% respectively. Furthermore, desensitisation experiments revealed that the aggregatory response of PMNs to PAF was only partially refractory to prior treatment with LTB4 whereas the aggregatory response to LTB4 was completely refractory to prior treatment with PAF. These results suggest that PAF-induced aggregation of rat PMNs is in part mediated by LTB4 and in part directly by an as yet unidentified mechanism.
Authors:
I Moodley; A Stuttle
Related Documents :
9192907 - Direct effects of platelet-activating factor on glomerular capillary permeability.
14565987 - Platelet-activating factor: a previously unrecognized mediator of fever.
20870297 - Platelet activating factor induces blood brain barrier permeability alteration in vitro.
8825027 - The vascular distribution of the platelet-activating factor receptor.
22234747 - Simultaneous measurement of adenosine triphosphate release and aggregation potentiates ...
7846097 - Inhibitory effect of prostaglandin e1 on human neutrophil function.
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Prostaglandins     Volume:  33     ISSN:  0090-6980     ISO Abbreviation:  Prostaglandins     Publication Date:  1987 Feb 
Date Detail:
Created Date:  1987-07-16     Completed Date:  1987-07-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0320271     Medline TA:  Prostaglandins     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  253-64     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine
Animals
Arachidonate 5-Lipoxygenase / antagonists & inhibitors
Cell Aggregation / drug effects
Leukotriene B4 / pharmacology,  physiology*
Male
Neutrophils / drug effects*,  metabolism
Platelet Activating Factor / antagonists & inhibitors,  pharmacology*
Pyrazoles / pharmacology
Pyrazolones*
Rats
Rats, Inbred Strains
Chemical
Reg. No./Substance:
0/Platelet Activating Factor; 0/Pyrazoles; 0/Pyrazolones; 59040-30-1/nafazatrom; 66000-40-6/4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; 71160-24-2/Leukotriene B4; EC 1.13.11.34/Arachidonate 5-Lipoxygenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro action of PG F2 alpha on progesterone and cAMP synthesis in small bovine luteal cells.
Next Document:  Analogs of leukotriene B4: effects of modification of the hydroxyl groups on leukocyte aggregation a...